Forwarded from Robin Monotti Channel + Mike Yeadon
I'm surprised that I can become even more appalled but I just have. They knew about ovarian concentration of certain carriers years ago. And used them anyway This is presumably why the Japanese regulatory agency requested that study. Mike Y.
https://www.sciencedirect.com/science/article/abs/pii/S01683659 Accumulation of nanocarriers in the ovary: A neglected toxicity risk
ARTICLE ABSTRACT: Several nanocarrier systems are frequently used in modern pharmaceutical therapies. Within this study a potential toxicity risk of all nanoscaled drug delivery systems was found. An accumulation of several structurally different nanocarriers but not of soluble polymers was detected in rodent ovaries after intravenous (i.v.) administration. Studies in different mouse species and Wistar rats were conducted and a --high local accumulation of nanoparticles, nanocapsules and nanoemulsions in specific locations of the ovaries was found in all animals--. We characterised the enrichment by in vivo and ex vivo multispectral fluorescence imaging and confocal laser scanning microscopy. The findings of this study emphasise the role of early and comprehensive in vivo studies in pharmaceutical research. Nanocarrier accumulation in the ovaries may also comprise an important toxicity issue in humans but the results might as well open a new field of targeted ovarian therapies.
